{"product_id":"arct-vrio-analysis","title":"Arcturus Therapeutics Holdings Inc. (ARCT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eWhat truly separates Arcturus Therapeutics Holdings Inc. (ARCT) from its competition? Our deep-dive VRIO analysis cuts straight to the core, evaluating the Value, Rarity, Inimitability, and Organization of its key assets (\u0026amp;O4\u0026amp;). Before you make another strategic move, uncover the definitive verdict on whether these elements forge an insurmountable advantage or mask a critical weakness - the full breakdown awaits below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eArcturus Therapeutics Holdings Inc. (ARCT) - VRIO Analysis: \u003cstrong\u003e1. STARR® Self-Amplifying mRNA (sa-mRNA) Technology\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core engine of Arcturus Therapeutics Holdings Inc. (ARCT) - their STARR® self-amplifying mRNA platform. This isn't just another flavor of mRNA; it’s designed to make your own cells do more of the heavy lifting. This technology is the reason they secured the world's first approval for an sa-mRNA COVID vaccine, KOSTAIVE®, in Japan back in 2023, and why they are pushing it into rare disease treatments like Cystic Fibrosis (ARCT-032) and OTC Deficiency (ARCT-810).\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on why this matters: the sa-mRNA instructs the body to amplify the mRNA and protein production itself. This translates directly into a lower required dose compared to standard mRNA vaccines. For instance, head-to-head data showed KOSTAIVE® achieved superior immunogenicity at just \u003cstrong\u003eone-sixth the dose\u003c\/strong\u003e of the comparator, using only \u003cstrong\u003e5 µg\u003c\/strong\u003e versus \u003cstrong\u003e30 µg\u003c\/strong\u003e of the conventional mRNA vaccine. This efficiency is a massive lever for cost and potentially patient tolerability, which is key as they look toward a US BLA filing for KOSTAIVE® in Q3 2025.\u003c\/p\u003e\n\n\u003ch3\u003eVRIO Framework for STARR® sa-mRNA Technology\u003c\/h3\u003e\n\u003cp\u003eWe assess the competitive position based on the four VRIO dimensions. The financial health as of the third quarter of 2025 shows a net loss of approximately \u003cstrong\u003e$36.7 million\u003c\/strong\u003e for the nine months ended September 30, 2025, but the cash runway is extended into \u003cstrong\u003e2028\u003c\/strong\u003e, giving them time to execute on this platform.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Rationale\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue (V)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eAllows for lower doses, validated by KOSTAIVE® using \u003cstrong\u003e5 µg\u003c\/strong\u003e vs. \u003cstrong\u003e30 µg\u003c\/strong\u003e standard mRNA. Supports pipeline advancement with cash runway into \u003cstrong\u003e2028\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRarity (R)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eThe only globally approved, proven sa-mRNA technology with a commercial product (KOSTAIVE®). Phase 1 H5N1 vaccine (ARCT-2304) tested doses of \u003cstrong\u003e1.5, 5, and 12 µg\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eImitability (I)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eReplication requires significant, specialized R\u0026amp;D investment and time to match the platform’s design and delivery characteristics.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOrganization (O)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eThe entire strategic focus is built around this platform for both vaccines and therapeutics. Operating expenses decreased year-over-year by \u003cstrong\u003e43.7%\u003c\/strong\u003e in Q2 2025 to \u003cstrong\u003e$39.9 million\u003c\/strong\u003e, showing resource alignment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch4\u003eCompetitive Advantage Scoring\u003c\/h4\u003e\n\u003cp\u003eThe STARR® platform currently demonstrates a clear competitive edge. The combination of Value, Rarity, and Organization points toward a sustained advantage, provided they can successfully translate this platform into approved therapeutics for rare diseases.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompetitive Parity: Standard mRNA technology.\u003c\/li\u003e\n\u003cli\u003eTemporary Advantage: Early mover advantage with KOSTAIVE® approval in Japan (2023).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSustained Competitive Advantage:\u003c\/strong\u003e The core sa-mRNA intellectual property and manufacturing know-how.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch4\u003eDose and Immunogenicity Comparison Example\u003c\/h4\u003e\n\u003cp\u003eWhen ARCT-154 was used as a second booster, the immune response metrics were notably higher than the conventional mRNA vaccine (BNT162b2) against the Wuhan-Hu-1 strain:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGMFR (Wuhan-Hu-1): ARCT-154: \u003cstrong\u003e6.8\u003c\/strong\u003e vs. BNT162b2: \u003cstrong\u003e4.4\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSCR (Wuhan-Hu-1): ARCT-154: \u003cstrong\u003e66.1%\u003c\/strong\u003e vs. BNT162b2: \u003cstrong\u003e51.2%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor their H5N1 vaccine candidate, ARCT-2304, Phase 1 data showed that the \u003cstrong\u003e1.5 µg\u003c\/strong\u003e, \u003cstrong\u003e5 µg\u003c\/strong\u003e, and \u003cstrong\u003e12 µg\u003c\/strong\u003e doses were all well-tolerated in \u003cstrong\u003e212\u003c\/strong\u003e participants. This reinforces the low-dose potential across different applications.\u003c\/p\u003e\n\n\u003cp\u003eIf onboarding for pivotal trials takes longer than expected, like the CF trial delay into 2027, the market might question the Organization component, even with the extended cash runway into \u003cstrong\u003e2028\u003c\/strong\u003e. Still, the technology itself remains rare.\u003c\/p\u003e\n\u003cp\u003eFinance: update the 13-week cash flow forecast to reflect the Q3 2025 net loss of \u003cstrong\u003e$13.5 million\u003c\/strong\u003e for the quarter.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eArcturus Therapeutics Holdings Inc. (ARCT) - VRIO Analysis: \u003cstrong\u003e2. LUNAR® Lipid-Mediated Delivery Platform\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This is the engine that gets the RNA payload into the right cells - crucial for systemic treatments like ARCT-810 (liver-targeted) and inhaled treatments like ARCT-032 (lung-targeted). Preclinical studies demonstrated robust expression, such as \u0026gt;90% of cells in the liver expressing luciferase in a model.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium-High. Delivery is the hardest part of RNA medicine, and LUNAR® has demonstrated proof-of-concept across different tissues. The platform utilizes a library of over 250 proprietary lipids.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors have their own delivery systems, but reverse-engineering the specific LUNAR® formulation is complex. The technology is protected by an extensive patent portfolio of over 400 patents and patent applications. Preclinical safety has been demonstrated up to 15 mg\/kg in NHP models for LUNAR-sa.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. It underpins their two lead rare disease candidates, showing consistent application. The platform supports collaborations that have generated approximately $473.1 million in upfront payments and milestones from CSL as of December 31, 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary to Sustained. Its proven success in multiple indications keeps it ahead, but delivery tech evolves fast. KOSTAIVE®, the first self-amplifying mRNA product, was authorized in Japan in November 2023 and the European Union in February 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePlatform Application\/Metric\u003c\/th\u003e\n\u003cth\u003eTarget Indication\/Asset\u003c\/th\u003e\n\u003cth\u003eDose\/Cohort Size Data\u003c\/th\u003e\n\u003cth\u003eKey Result\/Status Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLipid Library Size\u003c\/td\u003e\n\u003ctd\u003eLUNAR® Platform\u003c\/td\u003e\n\u003ctd\u003eOver 250 proprietary lipids\u003c\/td\u003e\n\u003ctd\u003eVersatile, customizable formulations demonstrated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver Targeting (Systemic)\u003c\/td\u003e\n\u003ctd\u003eARCT-810 (OTC Deficiency)\u003c\/td\u003e\n\u003ctd\u003ePhase 2 cohorts included 0.3 mg\/kg (N=8) and 0.5 mg\/kg dosing\u003c\/td\u003e\n\u003ctd\u003ePhase 2 interim data showed decreases in glutamine levels to within normal range\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLung Targeting (Inhaled)\u003c\/td\u003e\n\u003ctd\u003eARCT-032 (Cystic Fibrosis)\u003c\/td\u003e\n\u003ctd\u003ePhase 2 interim data from 3 participants at 5 mg and 6 participants at 10 mg daily doses over 28 days\u003c\/td\u003e\n\u003ctd\u003eObserved mucus plug reduction after 28 days of treatment in Class I CF adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccine Delivery\u003c\/td\u003e\n\u003ctd\u003eKOSTAIVE® (COVID-19)\u003c\/td\u003e\n\u003ctd\u003ePreclinical single dose of 2 µg showed 100% seroconversion\u003c\/td\u003e\n\u003ctd\u003eAuthorized in Japan (Nov 2023) and European Union (Feb 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe LUNAR® mechanism involves pH-mediated disruption enabling RNA payload release following rapid biodegradation of LUNAR® components upon endosome aging.\u003c\/li\u003e\n\u003cli\u003ePreclinical safety studies showed LUNAR® formulations were well tolerated up to 30 mg\/kg in mouse models and up to 15 mg\/kg in Non-Human Primate (NHP) models for LUNAR-sa.\u003c\/li\u003e\n\u003cli\u003eThe company's cash runway was expected to extend through the first quarter of fiscal year 2027 based on pipeline progression as of late 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eArcturus Therapeutics Holdings Inc. (ARCT) - VRIO Analysis: \u003cstrong\u003e3. ARCT-032 (Cystic Fibrosis) Clinical Program\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTargets Cystic Fibrosis, including Class I CF individuals who \u003cstrong\u003edo not produce CFTR\u003c\/strong\u003e and \u003cstrong\u003edo not respond\u003c\/strong\u003e to available CFTR modulator therapy. Interim Phase 2 data presented in October 2025 showed a meaningful trend of clinical activity.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing Cohort 2 Size\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eSix\u003c\/strong\u003e Class I CF adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing Duration (Cohort 2)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e28 days\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose (Cohort 2)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10 mg\u003c\/strong\u003e daily, inhaled\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMucus Burden Reduction (HRCT)\u003c\/td\u003e\n\u003ctd\u003eObserved in \u003cstrong\u003efour of six\u003c\/strong\u003e participants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNovel inhaled mRNA therapeutic utilizing the LUNAR\u003csup\u003e®\u003c\/sup\u003e platform for CF. Received \u003cstrong\u003eOrphan Medicinal Product Designation\u003c\/strong\u003e from the EMA and \u003cstrong\u003eOrphan Drug Designation\u003c\/strong\u003e from the FDA.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSpecific clinical data generated from the ongoing Phase 2 trial (NCT06747858) cannot be immediately replicated. The third cohort is enrolling up to \u003cstrong\u003esix subjects\u003c\/strong\u003e to assess the \u003cstrong\u003e15 mg\u003c\/strong\u003e dose daily over \u003cstrong\u003e28 days\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCommitment shown by proceeding with dose escalation and planning a longer study. The Company intends to initiate a \u003cstrong\u003e12-week\u003c\/strong\u003e safety and preliminary efficacy study in up to \u003cstrong\u003e20 CF participants\u003c\/strong\u003e in the \u003cstrong\u003efirst half of 2026\u003c\/strong\u003e (H1 2026). The Q3 2025 net loss was approximately $\u003cstrong\u003e13.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eClinical activity signals warranting advancement to a \u003cstrong\u003e12-week\u003c\/strong\u003e study.\u003c\/li\u003e\n\u003cli\u003eRegulatory designations secured: \u003cstrong\u003eOrphan Drug\u003c\/strong\u003e status.\u003c\/li\u003e\n\u003cli\u003ePlatform technology: LUNAR\u003csup\u003e®\u003c\/sup\u003e lipid-mediated aerosolized platform.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eArcturus Therapeutics Holdings Inc. (ARCT) - VRIO Analysis: \u003cstrong\u003e4. ARCT-810 (OTC Deficiency) Clinical Program\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePositive interim Phase 2 results demonstrate therapeutic promise for Ornithine Transcarbamylase ($\\text{OTC}$) Deficiency, a life-threatening genetic disorder where liver transplantation is the only known cure. The data provide the first evidence of an $\\text{mRNA}$ therapeutic improving urea cycle function.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomarker\/Metric\u003c\/td\u003e\n\u003ctd\u003eBaseline\/Control\u003c\/td\u003e\n\u003ctd\u003ePost-Treatment Result\u003c\/td\u003e\n\u003ctd\u003eStatistical Significance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelative Ureagenesis Function ($\\text{RUF}$)\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{29.0\\%}$ ($\\text{SD}; \\mathbf{9.1\\%}$)\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{43.7\\%}$ ($\\text{SD}; \\mathbf{21.7\\%}$) at $\\mathbf{28}$ days post-fifth dose\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{p-value} = \\mathbf{0.026}$ ($\\text{LMM}$)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eParticipants with $\\text{RUF} \u0026gt; \\mathbf{50\\%}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{0}$ out of $\\mathbf{3}$\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{2}$ out of $\\mathbf{3}$\u003c\/td\u003e\n\u003ctd\u003eIndicates clinically meaningful improvement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlutamine Levels (U.S. Open-Label)\u003c\/td\u003e\n\u003ctd\u003eElevated from baseline\u003c\/td\u003e\n\u003ctd\u003eDecreased to normal levels after $\\mathbf{3}$ doses\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{p-value} = \\mathbf{0.004}$ ($\\text{LMM}$)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmmonia Levels\u003c\/td\u003e\n\u003ctd\u003eStable\/Within normal range\u003c\/td\u003e\n\u003ctd\u003eMaintained within normal range following $\\ge \\mathbf{2}$ doses for $\\approx \\mathbf{28}$ days\u003c\/td\u003e\n\u003ctd\u003eObserved across both Phase 2 studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eTotal participants dosed across Phase 1\/1b and Phase 2 studies to date: $\\mathbf{40}$, with $\\mathbf{20}$ being $\\text{OTC}$ deficient participants. No serious Infusion-Related Reactions ($\\text{IRRs}$) observed with the improved $\\mathbf{3}$-hour $\\text{IV}$ regimen ($\\text{N} = \\mathbf{8}$; up to $\\mathbf{6}$ infusions).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. It is an advanced, wholly-owned program targeting a severe liver rare disease. The program has secured multiple designations:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOrphan Medicinal Product Designation ($\\text{EMA}$)\u003c\/li\u003e\n\u003cli\u003eOrphan Drug Designation ($\\text{FDA}$)\u003c\/li\u003e\n\u003cli\u003eFast Track Designation ($\\text{FDA}$)\u003c\/li\u003e\n\u003cli\u003eRare Pediatric Disease Designation ($\\text{FDA}$)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDifficult. The successful demonstration of biological effect, including $\\mathbf{2}$ of $\\mathbf{3}$ participants achieving $\\text{RUF} \u0026gt; \\mathbf{50\\%}$ and consistent glutamine normalization, combined with the proprietary $\\text{LUNAR}{\\circledR}$ delivery technology, creates a barrier. The regulatory pathway navigated to date, including securing multiple designations, is hard to copy quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eYes. The company is diligently preparing for meetings with the $\\text{FDA}$ and other regulatory agencies in $\\mathbf{H1 2026}$ to discuss the pivotal trial strategy for both pediatric and adult populations, with Phase 3 initiation expected in $\\mathbf{2026}$. Research and development expenses for the program contributed to a decrease to $\\mathbf{\\$29.6}$ million for the three months ended June 30, 2025, from $\\mathbf{\\$58.7}$ million in the prior year period. The company has extended its cash runway into $\\mathbf{2028}$.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained. Success in achieving regulatory alignment on the pivotal trial design in $\\mathbf{H1 2026}$ and subsequent positive Phase 3 outcomes could establish Arcturus Therapeutics as a leader in liver-targeted $\\text{RNA}$ medicines, leveraging its $\\text{LUNAR}{\\circledR}$ delivery technology.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eArcturus Therapeutics Holdings Inc. (ARCT) - VRIO Analysis: \u003cstrong\u003e5. KOSTAIVE® Commercial\/Regulatory Footprint\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe asset provides validation for the sa-mRNA platform, evidenced by regulatory achievements and associated financial triggers. The European Commission granted marketing authorization for KOSTAIVE® on \u003cstrong\u003eFebruary 14, 2025\u003c\/strong\u003e. Arcturus received the initial milestone payment from CSL following the EU approval. In Japan, Meiji Seika Pharma received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) in \u003cstrong\u003eAugust 2025\u003c\/strong\u003e for the two-dose vial of KOSTAIVE updated for the JN.1 variant XEC. The pivotal clinical study in Vietnam (NCT05012943) included \u003cstrong\u003e17,582\u003c\/strong\u003e participants who received at least one dose of the study vaccine.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU Marketing Authorization Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFebruary 14, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan Updated Vial Approval Date (PMDA)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAugust 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal CSL Milestones (as of Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$473.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKOSTAIVE® Share of Gross Profit (Q4 2024)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$28.0 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe initial designation as the world's first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine to be approved is unique. The original approval in Japan occurred in \u003cstrong\u003eNovember 2023\u003c\/strong\u003e. A commercial milestone of \u003cstrong\u003e$25 million\u003c\/strong\u003e was triggered by the first sale of KOSTAIVE® in Japan in \u003cstrong\u003eSeptember 2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe regulatory pathway for an sa-mRNA vaccine is now established through the EU and Japanese approvals. Other companies possess approved COVID-19 vaccines.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOrganizational alignment is demonstrated by the transition of commercialization responsibilities to CSL Seqirus and the joint venture ARCALIS in Japan for manufacturing. Revenue from the CSL collaboration reflected lower amortization as KOSTAIVE progressed toward commercialization. Revenue for the three months ended \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, was \u003cstrong\u003e$17.2 million\u003c\/strong\u003e, a decrease of \u003cstrong\u003e$24.5 million\u003c\/strong\u003e compared to the same period in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenue for the nine months ended \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e$74.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRevenue decrease for nine months ended \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e vs. \u003cstrong\u003e2024\u003c\/strong\u003e: \u003cstrong\u003e$54.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is temporary, linked to the ongoing need for COVID-19 vaccines and the achievement of future milestones. The company expects to receive future milestone payments from CSL supporting the ongoing development of the COVID program.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eArcturus Therapeutics Holdings Inc. (ARCT) - VRIO Analysis: \u003cstrong\u003e6. Extensive Intellectual Property Portfolio\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This portfolio, covering over \u003cstrong\u003e500\u003c\/strong\u003e patents and patent applications across the U.S., Europe, Japan, China, and other countries, acts as a defensive moat around their core technologies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium. Many biotechs have IP, but the breadth covering multiple RNA modalities (sa-mRNA, LUNAR®) is valuable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. The sheer volume and age of the patents are costly and time-consuming to challenge or replicate.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. IP protection is cited as covering all their key technologies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. It legally blocks competitors from using their specific innovations.\u003c\/p\u003e\n\u003cp\u003eThe financial realization of this intellectual property is evidenced by collaboration structures:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003cth\u003eAmount\/Scope\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patents and Applications (Latest Reported)\u003c\/td\u003e\n\u003ctd\u003eGeographic Coverage\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e500\u003c\/strong\u003e in the U.S., Europe, Japan, China, and other countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSL Collaboration Value Realized\u003c\/td\u003e\n\u003ctd\u003eUpfront Payments and Milestones Received (as of June 30, 2024)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$437.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore Technologies Covered\u003c\/td\u003e\n\u003ctd\u003ePlatform Inclusions\u003c\/td\u003e\n\u003ctd\u003eLUNAR® lipid-mediated delivery, STARR® mRNA technology (sa-mRNA), UNA chemistry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Filing Activity (Q2 2024)\u003c\/td\u003e\n\u003ctd\u003eDominant Office\u003c\/td\u003e\n\u003ctd\u003eEuropean Patent Office (EPO) accounted for nearly \u003cstrong\u003e25%\u003c\/strong\u003e of filings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe portfolio encompasses protection for various nucleic acid medicine types:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMessenger RNA (mRNA)\u003c\/li\u003e\n\u003cli\u003eSmall interfering RNA (siRNA)\u003c\/li\u003e\n\u003cli\u003eCircular RNA\u003c\/li\u003e\n\u003cli\u003eAntisense RNA\u003c\/li\u003e\n\u003cli\u003eSelf-amplifying RNA (sa-mRNA)\u003c\/li\u003e\n\u003cli\u003eDNA\u003c\/li\u003e\n\u003cli\u003eGene editing therapeutics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecific granted patents include those related to:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNucleic acid immunization via lipid-NA nanoparticle encapsulation (Patent Number: \u003cstrong\u003e12083224\u003c\/strong\u003e, Granted: September 10, 2024)\u003c\/li\u003e\n\u003cli\u003eNucleotides encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein (Patent Number: \u003cstrong\u003e12070509\u003c\/strong\u003e, Granted: August 27, 2024)\u003c\/li\u003e\n\u003cli\u003eMethod of lyophilizing lipid nanoparticles (Patent Number: \u003cstrong\u003e12178921\u003c\/strong\u003e, Granted: December 31, 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eArcturus Therapeutics Holdings Inc. (ARCT) - VRIO Analysis: \u003cstrong\u003e7. Strategic Collaboration with CSL Seqirus\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThis partnership provides global commercialization muscle and financial support through milestone payments for the vaccine franchise, which helped extend the cash runway into \u003cstrong\u003e2028\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe total potential value of the collaboration is estimated to be up to $4.3 billion or $4.2 billion.\u003c\/p\u003e\n\u003cp\u003eArcturus received an upfront payment of $200 million.\u003c\/p\u003e\n\u003cp\u003eAs of December 31, 2024, Arcturus had achieved a total of approximately $473.1 million in upfront payments and milestones from CSL.\u003c\/p\u003e\n\u003cp\u003eDuring the quarter ended December 31, 2024, CSL reported to Arcturus that Arcturus' share of gross profit from sales of KOSTAIVE was approximately $28.0 million.\u003c\/p\u003e\n\u003cp\u003eThe company reported receiving the initial European Union (EU) approval milestone payment from CSL in the first quarter of 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Component\u003c\/td\u003e\n\u003ctd\u003eAmount\/Terms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$200 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Development Milestones\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e$1.3 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Commercial Milestones\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e$3 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID-19 Vaccine Profit Share\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e40%\u003c\/strong\u003e net profit share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther Vaccines Royalty Share\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003edouble-digit\u003c\/strong\u003e royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eMedium. Large pharma partnerships are common, but this one is tied to a globally approved product. KOSTAIVE® is the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eDifficult. Building a relationship of this scale and trust takes years. The collaboration combines CSL Seqirus' established global vaccine commercial and manufacturing infrastructure with Arcturus' innovative STARR™ self-amplifying mRNA vaccine and LUNAR® delivery platform technologies.\u003c\/p\u003e\n\u003cp\u003eThe licensed technologies include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSTARR™ self-amplifying mRNA (sa-mRNA) technology.\u003c\/li\u003e\n\u003cli\u003eLUNAR® lipid-mediated delivery system.\u003c\/li\u003e\n\u003cli\u003emRNA drug substance and drug product manufacturing expertise.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eYes. The company successfully managed the transition of KOSTAIVE® commercial responsibilities to CSL Seqirus. Regulatory filings for KOSTAIVE® include an MAA filing in the United Kingdom anticipated in \u003cstrong\u003eQ2 2025\u003c\/strong\u003e, followed by a U.S. BLA filing expected in \u003cstrong\u003eQ3 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe collaboration scope includes vaccines against:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSARS-CoV-2 (COVID-19).\u003c\/li\u003e\n\u003cli\u003eInfluenza.\u003c\/li\u003e\n\u003cli\u003ePandemic preparedness.\u003c\/li\u003e\n\u003cli\u003eThree other globally prevalent respiratory infectious diseases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained. Long-term, deep partnerships are hard to break or replicate quickly. The collaboration provides CSL with an exclusive license in the fields of influenza, COVID-19 and other respiratory viral diseases.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eArcturus Therapeutics Holdings Inc. (ARCT) - VRIO Analysis: \u003cstrong\u003e8. ARCALIS Joint Venture in Japan\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e It secures dedicated, specialized manufacturing capacity for mRNA vaccines and therapeutics within a key Asian market, de-risking the supply chain. This capacity is supported by \\$165 million in total financial grants awarded to ARCALIS by the Japanese government to date.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. A dedicated JV structure for mRNA manufacturing in Japan is a unique operational asset. ARCALIS is positioned as Japan's first one-stop mRNA CDMO.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Requires capital commitment, finding the right local partner, and regulatory setup. The JV structure involved in-licensing mRNA manufacturing technology from Arcturus.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. It’s a clear organizational move to control manufacturing quality and access for a major market. Arcturus holds a 49% equity position in the JV, which is subject to dilution. Meiji Seika Pharma announced an investment in ARCALIS, Inc. in November 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. It provides a structural advantage in regional supply chain control, with a design to deliver vaccines within 100 days of the declaration of a target viral strain.\u003c\/p\u003e\n\u003cp\u003eThe operational and financial commitments related to the ARCALIS facility are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eSource\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Japanese Government Grants to Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$165 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor Drug Substance, Drug Product, and DNA template manufacturing capabilities.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Japanese Government Grants (Two Grants)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$115 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAwarded in December 2021 and October 2022.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eArcturus Equity Position in ARCALIS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e49%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSubject to dilution.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug Substance Facility Completion Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJuly 2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThe mRNA Drug Substance manufacturing facility was completed.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug Product Plant Construction Target Finish\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePlanned completion date for the drug product plant.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility Total Floor Space\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7,252 square meters\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEquivalent to more than 78,000 square feet.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey operational metrics and milestones for the ARCALIS facility include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe facility occupies an area of 1,933 square meters (nearly half an acre).\u003c\/li\u003e\n\u003cli\u003eThe annual capacity is 5kg of drug substance per year.\u003c\/li\u003e\n\u003cli\u003eThis capacity is sufficient to make mRNA substance for up to 1 billion doses of the shot, based on a 5mcg dose.\u003c\/li\u003e\n\u003cli\u003eThe facility is designed to provide cGMP-integrated vaccine manufacturing, from mRNA drug substance to bulk nanoparticle-formulated drug product.\u003c\/li\u003e\n\u003cli\u003eDomestically produced products with active pharmaceutical ingredients manufactured at ARCALIS's Minami-soma facilities are able to be shipped for commercial use in Japan as of the period reported in March 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eArcturus Therapeutics Holdings Inc. (ARCT) - VRIO Analysis: \u003cstrong\u003e9. Disciplined Financial Management \u0026amp; Cash Runway Extension\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe strategic decision to streamline resources and cut costs has extended the cash runway to \u003cstrong\u003e2028\u003c\/strong\u003e, providing stability to focus on high-value rare disease trials. Cash, cash equivalents and restricted cash were \u003cstrong\u003e$237.3 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMedium. Many companies cut costs, but Arcturus Therapeutics has successfully reallocated capital to secure a long runway into \u003cstrong\u003e2028\u003c\/strong\u003e while advancing two late-stage rare disease assets, ARCT-032 and ARCT-810.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEasy. Other companies can cut expenses, but the timing and success of this pivot are specific. The reduction in operating expenses demonstrates this execution.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eYes. Management explicitly made this strategic reallocation, leading to lower operating expenses.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal operating expenses for the three months ended September 30, 2025, were \u003cstrong\u003e$33.7 million\u003c\/strong\u003e compared with \u003cstrong\u003e$52.4 million\u003c\/strong\u003e for the three months ended September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the nine months ended September 30, 2025, were \u003cstrong\u003e$87.7 million\u003c\/strong\u003e compared with \u003cstrong\u003e$151.4 million\u003c\/strong\u003e for the nine months ended September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eThe company noted that for the three months ended June 30, 2025, operating expenses were \u003cstrong\u003e$39.9 million\u003c\/strong\u003e compared with \u003cstrong\u003e$71.0 million\u003c\/strong\u003e for the three months ended June 30, 2024, representing a \u003cstrong\u003e43.7%\u003c\/strong\u003e year-over-year drop in that quarter.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. This advantage is based on recent operational decisions; it must be maintained through execution. More details regarding cost reduction and runway will be provided on the year-end call in March.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003ePeriod Ended September 30, 2024\u003c\/td\u003e\n\u003ctd\u003ePeriod Ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents and Restricted Cash\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$293.9 million\u003c\/strong\u003e (as of December 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$237.3 million\u003c\/strong\u003e (as of September 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses (3 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$52.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$33.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses (9 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$191.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$119.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eManagement expects general and administrative expenses to continue to decrease slightly in fiscal year 2026.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516114198677,"sku":"arct-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/arct-vrio-analysis.png?v=1740147814","url":"https:\/\/dcf-model.com\/pt\/products\/arct-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}